Predict Parkinson progression with scan
- Trial ID
- NCT07380204
- Official Title
- In Vivo Quantification of Hsp90 in the Human Brain in Healthy Aging and Neurodegeneration Using the Novel PET Radioligand [11C]HSP990
- Goal
- Predict Parkinson progression with scan
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Study Type
- INTERVENTIONAL
- Enrollment
- 48 participants
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
Summary For Families
The goal is to map and measure Hsp90, a cellular "chaperone" protein that helps fold and clear damaged proteins, in the brains of people with Parkinson's, Alzheimer's, ALS, and healthy aging to learn how Hsp90 changes with neurodegeneration. The approach uses PET imaging with a new radioligand called [11C]HSP990 that binds Hsp90 so researchers can see where and how much of the protein is present; parts of the study check radiation dose, how reproducible the scans are, and whether the scan can be shortened. This is an imaging test, not a treatment, so it does not alter medications like levodopa. Eligible participants include people with clinically established Parkinson's aged 45 to 85 in Hoehn‑Yahr stages 1,3 with a prior abnormal DaT scan, people meeting diagnostic criteria for AD or ALS, and healthy volunteers roughly 18 to 70 who pass medical and MRI screening and can lie still for the scan.
Locations
- UZ Leuven, Leuven, Vlaam-Brabant, Belgium
Frequently Asked Questions
- What is this trial testing?
- This trial is studying [11C]HSP990 PET dosimetry. The goal is to map and measure Hsp90, a cellular "chaperone" protein that helps fold and clear damaged proteins, in the brains of people with Parkinson's, Alzheimer's, ALS, and healthy aging to learn how Hsp90 changes with neurodegeneration. The approach uses PET imaging with a new radioligand called [11C]HSP990 that binds Hsp90 so researchers can see where and how much of the protein is present; parts of the study check radiation dose, how reproducible the scans are, and whether the scan can be shortened. This is an imaging test, not a treatment, so it does not alter medications like levodopa. Eligible participants include people with clinically established Parkinson's aged 45 to 85 in Hoehn‑Yahr stages 1,3 with a prior abnormal DaT scan, people meeting diagnostic criteria for AD or ALS, and healthy volunteers roughly 18 to 70 who pass medical and MRI screening and can lie still for the scan.
- Who can participate?
- Participants must be between 18 Years and 70 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 3 months.
- Will I get the real drug or a placebo?
- It depends on the trial design. Some Parkinson's trials are placebo controlled, meaning a portion of participants get an inactive comparison while others get the experimental treatment. Some use crossover designs so everyone eventually receives the active treatment at some point. Observational trials do not use a placebo at all because they are not testing a new treatment. The consent form for any specific trial spells out the design and your odds of being assigned to placebo before you enroll.
- How often will I need to visit the study site?
- Visit frequency varies by trial. Many Parkinson's studies require an in person visit every 4 to 12 weeks during the active treatment phase, with shorter or longer gaps depending on the design. The site coordinator can give you the full visit schedule before you sign anything, so you know what the time commitment looks like.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Will travel or parking be reimbursed?
- Many trials reimburse for parking, mileage, and sometimes lodging if the site is far from your home. Reimbursement policies vary by sponsor and site. When you contact the trial team, ask specifically what is covered and how reimbursement is processed.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.